New findings from J.T. Zheng and co-authors in the area of gene therapy published

   "To improve jadomycin fermentation process, a genetic engineering strategy was designed to replace a 3.4-kb regulatory region of jad gene cluster that contains four regulatory genes (3' end 272 bp of jadW2, jadW3, jadR2, and jadR1) and the native promoter upstream of jadJ (P-J) with the ermEp* promoter sequence so that ermEp* drives the expression of the jadomycin biosynthetic genes from jadJ in the engineered strain. As expected, the mutant strain produced jadomycin B without ethanol treatment, and the yield increased to about twofold that of the stressed wild-type," wrote J.T. Zheng and colleagues.

   The researchers concluded: "These results indicated that manipulation of the regulation of a biosynthetic gene cluster is an effective strategy to increase product yield."

   Zheng and colleagues published their study in Applied Microbiology and Biotechnology (Engineering a regulatory region of jadomycin gene cluster to improve jadomycin B production in Streptomyces venezuelae. Applied Microbiology and Biotechnology, 2007;76(4):883-888).

   For additional information, contact K.Q. Yang, Chinese Academy Science, Institute Microbiology, State Key Laboratory Microbiology Resources, PO Box 2714, Beijing 100081, People's Republic of China.

   Publisher contact information for the journal Applied Microbiology and Biotechnology is: Springer, 233 Spring Street, New York, NY 10013, USA.

   Keywords: People's Republic of China, Beijing, Biotechnology, Gene Therapy, Genetics, Genomics.

   This article was prepared by Biotech Week editors from staff and other reports. Copyright 2007, Biotech Week via NewsRx.com.

Return to Gene Therapy Alert Section